Annovis Bio Files 8-K on Financials
Ticker: ANVS · Form: 8-K · Filed: Mar 21, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Mar 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, company-update
Related Tickers: ANVS
TL;DR
Annovis Bio (ANVS) filed an 8-K on March 21, 2025, detailing financial results and operations.
AI Summary
Annovis Bio, Inc. filed an 8-K on March 21, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as QR Pharma, Inc. and changed its name on December 2, 2009.
Why It Matters
This 8-K filing provides an update on Annovis Bio's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not contain significant new events or risks.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former company name
- March 21, 2025 (date) — Filing date
- December 2, 2009 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing by Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report on Annovis Bio, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 21, 2025.
What was Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc.
On what date did the company change its name from QR Pharma, Inc.?
The company changed its name from QR Pharma, Inc. on December 2, 2009.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive office address for Annovis Bio, Inc. is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 21, 2025 regarding Annovis Bio, Inc. (ANVS).